Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

107 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis.
Burmester GR, Weinblatt ME, McInnes IB, Porter D, Barbarash O, Vatutin M, Szombati I, Esfandiari E, Sleeman MA, Kane CD, Cavet G, Wang B, Godwood A, Magrini F; EARTH Study Group. Burmester GR, et al. Among authors: sleeman ma. Ann Rheum Dis. 2013 Sep 1;72(9):1445-52. doi: 10.1136/annrheumdis-2012-202450. Epub 2012 Dec 12. Ann Rheum Dis. 2013. PMID: 23234647 Free PMC article. Clinical Trial.
A randomised phase IIb study of mavrilimumab, a novel GM-CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritis.
Burmester GR, McInnes IB, Kremer J, Miranda P, Korkosz M, Vencovsky J, Rubbert-Roth A, Mysler E, Sleeman MA, Godwood A, Sinibaldi D, Guo X, White WI, Wang B, Wu CY, Ryan PC, Close D, Weinblatt ME; EARTH EXPLORER 1 study investigators. Burmester GR, et al. Among authors: sleeman ma. Ann Rheum Dis. 2017 Jun;76(6):1020-1030. doi: 10.1136/annrheumdis-2016-210624. Epub 2017 Feb 17. Ann Rheum Dis. 2017. PMID: 28213566 Free article. Clinical Trial.
Preclinical characterisation of the GM-CSF receptor as a therapeutic target in rheumatoid arthritis.
Greven DE, Cohen ES, Gerlag DM, Campbell J, Woods J, Davis N, van Nieuwenhuijze A, Lewis A, Heasmen S, McCourt M, Corkill D, Dodd A, Elvin J, Statache G, Wicks IP, Anderson IK, Nash A, Sleeman MA, Tak PP. Greven DE, et al. Among authors: sleeman ma. Ann Rheum Dis. 2015 Oct;74(10):1924-30. doi: 10.1136/annrheumdis-2014-205234. Epub 2014 Jun 16. Ann Rheum Dis. 2015. PMID: 24936585 Free PMC article.
Protein engineering and preclinical development of a GM-CSF receptor antibody for the treatment of rheumatoid arthritis.
Minter RR, Cohen ES, Wang B, Liang M, Vainshtein I, Rees G, Eghobamien L, Harrison P, Sims DA, Matthews C, Wilkinson T, Monk P, Drinkwater C, Fabri L, Nash A, McCourt M, Jermutus L, Roskos L, Anderson IK, Sleeman MA. Minter RR, et al. Among authors: sleeman ma. Br J Pharmacol. 2013 Jan;168(1):200-11. doi: 10.1111/j.1476-5381.2012.02173.x. Br J Pharmacol. 2013. PMID: 22913645 Free PMC article.
GM-CSF as a therapeutic target in inflammatory diseases.
van Nieuwenhuijze A, Koenders M, Roeleveld D, Sleeman MA, van den Berg W, Wicks IP. van Nieuwenhuijze A, et al. Among authors: sleeman ma. Mol Immunol. 2013 Dec;56(4):675-82. doi: 10.1016/j.molimm.2013.05.002. Epub 2013 Aug 8. Mol Immunol. 2013. PMID: 23933508 Review.
107 results